CBRS Stock: Cerebras Lock-Up Expires Ahead of Nov. 12 Q3…

Cerebras Systems (NASDAQ: CBRS) shares were trading at $93.79, up 4.58%, at 11:44 a.m. ET on Monday, November 9, as the company’s main IPO lock-up period expired at 6:00 a.m. ET. The release of remaining restricted shares comes three days before Cerebras reports its third-quarter 2026 financial results, giving investors two closely timed developments to assess as the stock trades approximately 49.3% below its $185 IPO price.The timing is particularly sensitive after several senior executives disclosed substantial share sales during the previous months. Chief Technology Officer Sean Lie sold 710,247 shares in August under a Rule 10b5-1 trading plan, while Chief Operating Officer Dhiraj Mallick completed a separate 396,000-share sale in September under another prearranged plan. Both executives also reported other transactions, including sales associated with equity compensation.Meanwhile, the shares have experienced considerable volatility since the IPO. CBRS reached an intraday low of $77.84 on November 5 before recovering to close at $89.68 on November 6. The current rebound does little to change the broader picture: the stock remains substantially below its offering price, while the upcoming earnings report and the availability of additional insider shares could influence trading conditions.

The Prospectus Sets November 9, Not November 10

The exact lock-up expiration date is established by Cerebras’ final IPO prospectus, filed with the SEC on May 14 but dated May 13, 2026. The document states that the main lock-up period ends at the earlier of two dates: 6:00 a.m. Eastern Time on the second trading day following the company’s release of earnings for the quarter ending September 30, 2026, or 180 days after the prospectus date.The 180-day provision produces November 9, 2026. The alternative earnings-linked date falls on November 16. Cerebras announced that its third-quarter results would be released after the market closes on Thursday, November 12. Friday, November 13 is the first trading day following the announcement, making Monday, November 16 the second trading day. The earlier November 9 date therefore controls.This resolves the discrepancy with MarketBeat, which identified November 10 as the expiration date. The difference appears to stem from using May 14, the filing date, rather than May 13, the date printed on the final prospectus. The controlling wording refers to the prospectus date, making November 9 the applicable deadline.The prospectus says Cerebras, its executive officers and directors, and certain other record holders representing approximately 71.4% of its Class A common stock and related convertible securities entered into lock-up agreements. Additional holders were subject to separate market-standoff provisions.Cerebras also estimated that up to approximately 171.1 million shares could become eligible for release through early-release provisions during the overall lock-up period, including up to 15 million shares held by directors and officers. That figure represents an aggregate estimate across the release schedule, not the number of shares becoming available on November 9 alone.The final provision makes all remaining shares held by stockholders not previously eligible for sale potentially available, subject to applicable Rule 144 restrictions, including limitations affecting company affiliates. The expiration therefore removes the contractual lock-up restriction but does not mean every newly eligible share will immediately enter the market.

SEC Filings Show What Executives Have Already Sold

Insider filings provide a more detailed picture than the headline figures circulating ahead of the lock-up expiration. Sean Lie’s Form 144 filings disclose that he sold 710,247 shares on August 20 for gross proceeds of approximately $147.63 million under a Rule 10b5-1 trading plan adopted on May 20.The distinction is important because the 710,247 shares were already sold, not a new proposed sale associated with the November 9 expiration. His October 27 Form 144 instead proposed a separate sale of 60,000 shares, with an estimated market value of approximately $6.5 million. A Form 4 filed the following day confirmed that all 60,000 shares were sold on October 27 under the same prearranged trading plan.Mallick’s transactions also require separating discretionary sales from tax-related disposals. His August 18 Form 4 reported the sale of 38,889 shares for approximately $8.64 million. The filing explicitly identified this as a sell-to-cover transaction to satisfy tax withholding obligations following the settlement of restricted stock units. It stated that the transaction was not discretionary.However, Mallick subsequently completed a substantially larger transaction. On September 29, he sold 396,000 shares for approximately $80.8 million under a Rule 10b5-1 trading plan adopted on June 30. His Form 144 filed that day disclosed the proposed transaction, while the Form 4 filed on September 30 confirmed its execution.These filings establish that meaningful insider selling had already taken place before the final lock-up expiration. They also show why different transactions should not be treated as equivalent: some were executed under prearranged trading plans, while the August transaction involved tax withholding. The newly expired lock-up creates additional potential selling flexibility, but it does not establish that these executives intend to dispose of further shares immediately.

What November 12 Earnings Need to Answer

Cerebras will report its third-quarter 2026 results after the US market closes on Thursday, November 12, with a conference call scheduled for 5 p.m. ET. The report will give investors their next opportunity to assess whether the company’s rapid expansion in AI inference is translating into improving financial performance.For the third quarter, management previously guided for core revenue of approximately $214 million to $216 million, core gross margin of 38% to 40%, and core operating margin of negative 25% to negative 23%. These are non-GAAP core measures, rather than the company’s GAAP financial results.In the second quarter, Cerebras reported GAAP revenue of $180.1 million and core revenue of approximately $209.9 million. Core gross margin reached 41%, compared with a GAAP gross margin of approximately 14%. The difference reflects adjustments including customer warrant amortization, stock-based compensation, data center pass-through revenue and costs, and other specified items.The distinction will matter when investors assess the third-quarter performance. Cerebras needs to demonstrate that revenue growth is accompanied by sustainable improvements in underlying economics, particularly as it expands its manufacturing and data center capacity.Customer commitments will also receive attention. Cerebras reported $25.4 billion in remaining performance obligations as of June 30, 2026, a significant amount of which was attributable to its agreement with OpenAI. Under that arrangement, OpenAI committed to purchase 750 megawatts of AI inference capacity and has an option for an additional 1.25 gigawatts.Cerebras recognized $56.8 million in revenue from the OpenAI arrangement during the second quarter, net of customer warrant amortization. Investors will want to understand how the agreement is progressing, how quickly committed capacity is being deployed and how much of the reported backlog can translate into recognized revenue over the coming quarters.The company also reported that more than 600 megawatts of data center capacity was live or under contract for delivery by the end of 2027. Its ability to convert those commitments into operational capacity without excessive cost increases will be another important consideration, particularly given its substantial investment requirements.

Culper’s Wafer-Life Claim Meets Cerebras’ Rebuttal

The lock-up expiration and upcoming earnings report come against the background of a short-selling report published by Culper Research on October 28. The research firm disclosed a short position in Cerebras and alleged that its wafer-scale processors have a useful field lifespan of approximately 1.5 to 2.5 years, substantially shorter than investors might expect from the company’s technology claims.Culper also questioned Cerebras’ claims about its proprietary connector technology, alleging that the company uses an older third-party material known as PariPoser. The report further argued that Cerebras relies on continuous dummy operations to prevent temperature changes that could damage its wafer-scale chips, resulting in elevated power consumption.Cerebras CEO Andrew Feldman directly addressed the allegations in a November 5 company statement titled “What It Took to Build Wafer-Scale, and Why It Lasts.” Feldman rejected the two-year lifespan estimate and said the company had never shipped a system using PariPoser. He explained that controlled power consumption and temperature management are deliberate engineering techniques designed to prevent mechanical stress across the wafer.The company also stated that less than 0.5% of its deployed CS-3 wafers had been decommissioned since the system’s introduction in 2024. According to Feldman, TSMC qualifies the wafer for 10 years of continuous operation at 105 degrees Celsius, while the average junction temperature across Cerebras’ deployed CS-3 fleet remains below 65 degrees.Cerebras additionally explained that its accounting estimate for equipment useful life changed from one to three years to three to five years as its internally used equipment shifted from research and development toward production systems supporting its cloud business. Feldman said the revised estimate reflects the different operating environment and is subject to the company’s annual audit process.These statements represent Cerebras’ response to the short seller’s allegations, not independent confirmation that every reliability concern has been resolved. Feldman also disclosed that he is long Cerebras stock, a relevant consideration when assessing the company’s rebuttal.For investors, the issue extends beyond the immediate share-price reaction. If the company’s systems have shorter useful lives than its accounting estimates suggest, that could affect hardware economics, customer returns and the financial assumptions supporting its long-term commitments. Conversely, if Cerebras can demonstrate reliable deployments and sustained customer demand, the short seller’s central thesis would face a significant challenge.CBRS now enters a concentrated period of potential share supply and fundamental scrutiny. The main lock-up has expired, but the November 12 earnings report will provide a more direct assessment of revenue growth, margins, customer commitments and infrastructure execution. With the stock still approximately 49% below its IPO price, investors will be looking for evidence that the company’s commercial progress can support its valuation beyond the initial public offering excitement.